Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 13/2023

26.08.2023 | Original Article

A common [18F]-FDG PET radiomic signature to predict survival in patients with HPV-induced cancers

verfasst von: Stephane Niyoteka, Romain-David Seban, Rahimeh Rouhi, Andrew Scarsbrook, Catherine Genestie, Marion Classe, Alexandre Carré, Roger Sun, Agustina La Greca Saint-Esteven, Cyrus Chargari, Jack McKenna, Garry McDermott, Eirik Malinen, Stephanie Tanadini-Lang, Matthias Guckenberger, Marianne G. Guren, Claire Lemanski, Eric Deutsch, Charlotte Robert

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 13/2023

Einloggen, um Zugang zu erhalten

Abstract

Locally advanced cervical cancer (LACC) and anal and oropharyngeal squamous cell carcinoma (ASCC and OPSCC) are mostly caused by oncogenic human papillomaviruses (HPV). In this paper, we developed machine learning (ML) models based on clinical, biological, and radiomic features extracted from pre-treatment fluorine-18-fluorodeoxyglucose positron emission tomography ([18F]-FDG PET) images to predict the survival of patients with HPV-induced cancers. For this purpose, cohorts from five institutions were used: two cohorts of patients treated for LACC including 104 patients from Gustave Roussy Campus Cancer (Center 1) and 90 patients from Leeds Teaching Hospitals NHS Trust (Center 2), two datasets of patients treated for ASCC composed of 66 patients from Institut du Cancer de Montpellier (Center 3) and 67 patients from Oslo University Hospital (Center 4), and one dataset of 45 OPSCC patients from the University Hospital of Zurich (Center 5). Radiomic features were extracted from baseline [18F]-FDG PET images. The ComBat technique was applied to mitigate intra-scanner variability. A modified consensus nested cross-validation for feature selection and hyperparameter tuning was applied on four ML models to predict progression-free survival (PFS) and overall survival (OS) using harmonized imaging features and/or clinical and biological variables as inputs. Each model was trained and optimized on Center 1 and Center 3 cohorts and tested on Center 2, Center 4, and Center 5 cohorts. The radiomic-based CoxNet model achieved C-index values of 0.75 and 0.78 for PFS and 0.76, 0.74, and 0.75 for OS on the test sets. Radiomic feature-based models had superior performance compared to the bioclinical ones, and combining radiomic and bioclinical variables did not improve the performances. Metabolic tumor volume (MTV)-based models obtained lower C-index values for a majority of the tested configurations but quite equivalent performance in terms of time-dependent AUCs (td-AUC). The results demonstrate the possibility of identifying common PET-based image signatures for predicting the response of patients with induced HPV pathology, validated on multi-center multiconstructor data.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Brianti P, De Flammineis E, Mercuri SR. Review of HPV-related diseases and cancers. New Microbiol. 2017;40(2):80–5.PubMed Brianti P, De Flammineis E, Mercuri SR. Review of HPV-related diseases and cancers. New Microbiol. 2017;40(2):80–5.PubMed
2.
Zurück zum Zitat de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–70.PubMedPubMedCentralCrossRef de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–70.PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Araldi RP, Sant’Ana TA, Módolo DG, de Melo TC, Spadacci-Morena DD, de Cassia Stocco R, et al. The human papillomavirus (HPV)-related cancer biology: an overview. Biomed Pharmacother. 2018;106:1537–56.PubMedCrossRef Araldi RP, Sant’Ana TA, Módolo DG, de Melo TC, Spadacci-Morena DD, de Cassia Stocco R, et al. The human papillomavirus (HPV)-related cancer biology: an overview. Biomed Pharmacother. 2018;106:1537–56.PubMedCrossRef
7.
Zurück zum Zitat Hong A, Lee CS, Jones D, Veillard AS, Zhang M, Zhang X, et al. Rising prevalence of human papillomavirus-related oropharyngeal cancer in Australia over the last 2 decades. Head Neck. 2016;38(5):743–50.PubMedCrossRef Hong A, Lee CS, Jones D, Veillard AS, Zhang M, Zhang X, et al. Rising prevalence of human papillomavirus-related oropharyngeal cancer in Australia over the last 2 decades. Head Neck. 2016;38(5):743–50.PubMedCrossRef
8.
Zurück zum Zitat Taylor A, Eade T, Veivers D, Gill AJ, Pang L. Human papillomavirus and oropharyngeal squamous cell carcinoma: a 12-year retrospective review in a New South Wales tertiary referral centre. Austral J Otolaryngol. 2019;2:1. Publisher: AME Publishing Company. Available from: https://www.theajo.com/article/view/4143.CrossRef Taylor A, Eade T, Veivers D, Gill AJ, Pang L. Human papillomavirus and oropharyngeal squamous cell carcinoma: a 12-year retrospective review in a New South Wales tertiary referral centre. Austral J Otolaryngol. 2019;2:1. Publisher: AME Publishing Company. Available from: https://​www.​theajo.​com/​article/​view/​4143.CrossRef
9.
Zurück zum Zitat Mucosal Gheit T. Infections cutaneous human papillomavirus. Biology Cancer Front Oncol. 2019;9:355.PubMedCrossRef Mucosal Gheit T. Infections cutaneous human papillomavirus. Biology Cancer Front Oncol. 2019;9:355.PubMedCrossRef
10.
Zurück zum Zitat Darragh TM, Winkler B. Anal cancer and cervical cancer screening: key differences. Cancer Cytopathol. 2011;119(1):5–19.PubMedCrossRef Darragh TM, Winkler B. Anal cancer and cervical cancer screening: key differences. Cancer Cytopathol. 2011;119(1):5–19.PubMedCrossRef
11.
Zurück zum Zitat Nigro ND, Vaitkevicius VK, Buroker T, Bradley GT, Considine B. Combined therapy for cancer of the anal canal. Dis Colon Rectum. 1981;24(2):73–5.PubMedCrossRef Nigro ND, Vaitkevicius VK, Buroker T, Bradley GT, Considine B. Combined therapy for cancer of the anal canal. Dis Colon Rectum. 1981;24(2):73–5.PubMedCrossRef
12.
Zurück zum Zitat Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. JCO. 1997;15(5):2040–9. https://doi.org/10.1200/JCO.1997.15.5.2040.CrossRef Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. JCO. 1997;15(5):2040–9. https://​doi.​org/​10.​1200/​JCO.​1997.​15.​5.​2040.CrossRef
13.
Zurück zum Zitat Rivin Del Campo E, Matzinger O, Haustermans K, Peiffert D, Glynne-Jones R, Winter KA, et al. Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC). Eur J Cancer. 2019;121:130–43.PubMedPubMedCentralCrossRef Rivin Del Campo E, Matzinger O, Haustermans K, Peiffert D, Glynne-Jones R, Winter KA, et al. Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC). Eur J Cancer. 2019;121:130–43.PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Grégoire V, Lefebvre JL, Licitra L, Felip E, EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v184-186.PubMedCrossRef Grégoire V, Lefebvre JL, Licitra L, Felip E, EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v184-186.PubMedCrossRef
16.
Zurück zum Zitat Sturdza A, Pötter R, Fokdal LU, Haie-Meder C, Tan LT, Mazeron R, et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol. 2016;120(3):428–33.PubMedCrossRef Sturdza A, Pötter R, Fokdal LU, Haie-Meder C, Tan LT, Mazeron R, et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol. 2016;120(3):428–33.PubMedCrossRef
17.
Zurück zum Zitat Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriguez-Bigas MA, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007;68(3):794–800.PubMedCrossRef Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriguez-Bigas MA, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007;68(3):794–800.PubMedCrossRef
18.
Zurück zum Zitat Salani R, Khanna N, Frimer M, Bristow RE, Chen LM. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol. 2017;146(1):3–10.PubMedCrossRef Salani R, Khanna N, Frimer M, Bristow RE, Chen LM. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol. 2017;146(1):3–10.PubMedCrossRef
19.
Zurück zum Zitat Slørdahl KS, Klotz D, Olsen JG, Skovlund E, Undseth C, Abildgaard HL, et al. Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer. Acta Oncol. 2021;60(7):921–30.PubMedCrossRef Slørdahl KS, Klotz D, Olsen JG, Skovlund E, Undseth C, Abildgaard HL, et al. Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer. Acta Oncol. 2021;60(7):921–30.PubMedCrossRef
21.
Zurück zum Zitat Bhuva NJ, Glynne-Jones R, Sonoda L, Wong WL, Harrison MK. To PET or not to PET? That is the question. Staging in anal cancer. Ann Oncol. 2012;23(8):2078–82.PubMedCrossRef Bhuva NJ, Glynne-Jones R, Sonoda L, Wong WL, Harrison MK. To PET or not to PET? That is the question. Staging in anal cancer. Ann Oncol. 2012;23(8):2078–82.PubMedCrossRef
22.
Zurück zum Zitat Caldarella C, Annunziata S, Treglia G, Sadeghi R, Ayati N, Giovanella L. Diagnostic performance of positron emission tomography/computed tomography using fluorine-18 fluorodeoxyglucose in detecting locoregional nodal involvement in patients with anal canal cancer: a systematic review and meta-analysis. SciWorldJ. 2014;2014:196068. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932262/. Caldarella C, Annunziata S, Treglia G, Sadeghi R, Ayati N, Giovanella L. Diagnostic performance of positron emission tomography/computed tomography using fluorine-18 fluorodeoxyglucose in detecting locoregional nodal involvement in patients with anal canal cancer: a systematic review and meta-analysis. SciWorldJ. 2014;2014:196068. Available from: https://​www.​ncbi.​nlm.​nih.​gov/​pmc/​articles/​PMC3932262/​.
23.
Zurück zum Zitat Trautmann TG, Zuger JH. Positron Emission Tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol. 2005;7(4):309–13.PubMedCrossRef Trautmann TG, Zuger JH. Positron Emission Tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol. 2005;7(4):309–13.PubMedCrossRef
26.
Zurück zum Zitat Herrera FG, Breuneval T, Prior JO, Bourhis J, Ozsahin M. [(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy. Radiat Oncol. 2016;11:43.PubMedPubMedCentralCrossRef Herrera FG, Breuneval T, Prior JO, Bourhis J, Ozsahin M. [(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy. Radiat Oncol. 2016;11:43.PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Castelli J, De Bari B, Depeursinge A, Simon A, Devillers A, Roman Jimenez G, et al. Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy. Crit Rev Oncol Hematol. 2016;108:40–51.PubMedCrossRef Castelli J, De Bari B, Depeursinge A, Simon A, Devillers A, Roman Jimenez G, et al. Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy. Crit Rev Oncol Hematol. 2016;108:40–51.PubMedCrossRef
29.
Zurück zum Zitat Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RGPM, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48(4):441–6.PubMedPubMedCentralCrossRef Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RGPM, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48(4):441–6.PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Lucia F, Visvikis D, Valliéres M, Desseroit MC, Miranda O, Robin P, et al. External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2019;46(4):864–77.PubMedCrossRef Lucia F, Visvikis D, Valliéres M, Desseroit MC, Miranda O, Robin P, et al. External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2019;46(4):864–77.PubMedCrossRef
32.
35.
Zurück zum Zitat Beaumont J, Acosta O, Devillers A, Palard-Novello X, Chajon E, de Crevoisier R, et al. Voxel-based identification of local recurrence sub-regions from pre-treatment PET/CT for locally advanced head and neck cancers. EJNMMI Res. 2019;9(1):90.PubMedPubMedCentralCrossRef Beaumont J, Acosta O, Devillers A, Palard-Novello X, Chajon E, de Crevoisier R, et al. Voxel-based identification of local recurrence sub-regions from pre-treatment PET/CT for locally advanced head and neck cancers. EJNMMI Res. 2019;9(1):90.PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Brown PJ, Zhong J, Frood R, Currie S, Gilbert A, Appelt AL, et al. Prediction of outcome in anal squamous cell carcinoma using radiomic feature analysis of pre-treatment FDG PET-CT. Eur J Nucl Med Mol Imaging. 2019;46(13):2790–9.PubMedPubMedCentralCrossRef Brown PJ, Zhong J, Frood R, Currie S, Gilbert A, Appelt AL, et al. Prediction of outcome in anal squamous cell carcinoma using radiomic feature analysis of pre-treatment FDG PET-CT. Eur J Nucl Med Mol Imaging. 2019;46(13):2790–9.PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Bogowicz M, Riesterer O, Stark LS, Studer G, Unkelbach J, Guckenberger M, et al. Comparison of PET and CT radiomics for prediction of local tumor control in head and neck squamous cell carcinoma. Acta Oncol. 2017;56(11):1531–6.PubMedCrossRef Bogowicz M, Riesterer O, Stark LS, Studer G, Unkelbach J, Guckenberger M, et al. Comparison of PET and CT radiomics for prediction of local tumor control in head and neck squamous cell carcinoma. Acta Oncol. 2017;56(11):1531–6.PubMedCrossRef
40.
Zurück zum Zitat Mu W, Liang Y, Hall LO, Tan Y, Balagurunathan Y, Wenham R, et al. 18F-FDG PET/CT habitat radiomics predicts outcome of patients with cervical cancer treated with chemoradiotherapy. Radiol Artif Intell. 2020;2(6): e190218.PubMedPubMedCentralCrossRef Mu W, Liang Y, Hall LO, Tan Y, Balagurunathan Y, Wenham R, et al. 18F-FDG PET/CT habitat radiomics predicts outcome of patients with cervical cancer treated with chemoradiotherapy. Radiol Artif Intell. 2020;2(6): e190218.PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Cong H, Peng W, Tian Z, Valliéres M, Chuanpei X, Aijun Z, et al. FDG-PET/CT radiomics models for the early prediction of locoregional recurrence in head and neck cancer. Curr Med Imaging. 2021;17(3):374–83.PubMedCrossRef Cong H, Peng W, Tian Z, Valliéres M, Chuanpei X, Aijun Z, et al. FDG-PET/CT radiomics models for the early prediction of locoregional recurrence in head and neck cancer. Curr Med Imaging. 2021;17(3):374–83.PubMedCrossRef
43.
Zurück zum Zitat Valliéres M, Kay-Rivest E, Perrin LJ, Liem X, Furstoss C, Aerts HJWL, et al. Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer. Sci Rep. 2017;7(1):10117.PubMedPubMedCentralCrossRef Valliéres M, Kay-Rivest E, Perrin LJ, Liem X, Furstoss C, Aerts HJWL, et al. Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer. Sci Rep. 2017;7(1):10117.PubMedPubMedCentralCrossRef
44.
45.
Zurück zum Zitat Grégoire V, Evans M, Le QT, Bourhis J, Budach V, Chen A, et al. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO SSHNO TROG consensus guidelines. Radiother Oncol. 2018;126(1):3–24.PubMedCrossRef Grégoire V, Evans M, Le QT, Bourhis J, Budach V, Chen A, et al. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO SSHNO TROG consensus guidelines. Radiother Oncol. 2018;126(1):3–24.PubMedCrossRef
46.
Zurück zum Zitat Brierley JD, Gospodarowicz MK, Wittekind C, editors. The TNM classification of malignant tumours. 8. Oxford: Wiley Blackwell; 2017. Brierley JD, Gospodarowicz MK, Wittekind C, editors. The TNM classification of malignant tumours. 8. Oxford: Wiley Blackwell; 2017.
50.
Zurück zum Zitat van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 2017;77(21):e104–7.PubMedPubMedCentralCrossRef van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 2017;77(21):e104–7.PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat Fortin JP, Parker D, Tunç B, Watanabe T, Elliott MA, Ruparel K, et al. Harmonization of multi-site diffusion tensor imaging data. Neuroimage. 2017;161:149–70.PubMedCrossRef Fortin JP, Parker D, Tunç B, Watanabe T, Elliott MA, Ruparel K, et al. Harmonization of multi-site diffusion tensor imaging data. Neuroimage. 2017;161:149–70.PubMedCrossRef
59.
Zurück zum Zitat Lima GM, Matti A, Vara G, Dondi G, Naselli N, De Crescenzo EM, et al. Prognostic value of posttreatment 18F-FDG PET/CT and predictors of metabolic response to therapy in patients with locally advanced cervical cancer treated with concomitant chemoradiation therapy: an analysis of intensity- and volume-based PET parameters. Eur J Nucl Med Mol Imaging. 2018;45(12):2139–46. https://doi.org/10.1007/s00259-018-4077-1.CrossRefPubMedPubMedCentral Lima GM, Matti A, Vara G, Dondi G, Naselli N, De Crescenzo EM, et al. Prognostic value of posttreatment 18F-FDG PET/CT and predictors of metabolic response to therapy in patients with locally advanced cervical cancer treated with concomitant chemoradiation therapy: an analysis of intensity- and volume-based PET parameters. Eur J Nucl Med Mol Imaging. 2018;45(12):2139–46. https://​doi.​org/​10.​1007/​s00259-018-4077-1.CrossRefPubMedPubMedCentral
60.
Zurück zum Zitat Gauthé M, Richard-Molard M, Fayard J, Alberini JL, Cacheux W, Liévre A. Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer. Eur J Nucl Med Mol Imaging. 2017;44(1):63–70.PubMedCrossRef Gauthé M, Richard-Molard M, Fayard J, Alberini JL, Cacheux W, Liévre A. Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer. Eur J Nucl Med Mol Imaging. 2017;44(1):63–70.PubMedCrossRef
61.
Zurück zum Zitat Rijo-Cedeño J, Mucientes J, Álvarez O, Royuela A, Seijas Marcos S, Romero J, et al. Metabolic tumor volume and total lesion glycolysis as prognostic factors in head and neck cancer: systematic review and meta-analysis. Head Neck. 2020;42(12):3744–54.PubMedCrossRef Rijo-Cedeño J, Mucientes J, Álvarez O, Royuela A, Seijas Marcos S, Romero J, et al. Metabolic tumor volume and total lesion glycolysis as prognostic factors in head and neck cancer: systematic review and meta-analysis. Head Neck. 2020;42(12):3744–54.PubMedCrossRef
63.
Zurück zum Zitat El Naqa I, Grigsby P, Apte A, Kidd E, Donnelly E, Khullar D, et al. Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recognit. 2009;42(6):1162–71.PubMedPubMedCentralCrossRef El Naqa I, Grigsby P, Apte A, Kidd E, Donnelly E, Khullar D, et al. Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recognit. 2009;42(6):1162–71.PubMedPubMedCentralCrossRef
64.
Zurück zum Zitat Deantonio L, Milia ME, Cena T, Sacchetti G, Perotti C, Brambilla M, et al. Anal cancer FDG-PET standard uptake value: correlation with tumor characteristics, treatment response and survival. Radiol Med. 2016;121(1):54–9.PubMedCrossRef Deantonio L, Milia ME, Cena T, Sacchetti G, Perotti C, Brambilla M, et al. Anal cancer FDG-PET standard uptake value: correlation with tumor characteristics, treatment response and survival. Radiol Med. 2016;121(1):54–9.PubMedCrossRef
65.
Zurück zum Zitat Gillies RJ, Anderson AR, Gatenby RA, Morse DL. The biology underlying molecular imaging in oncology: from genome to anatome and back again. Clin Radiol. 2010;65(7):517–21.PubMedPubMedCentralCrossRef Gillies RJ, Anderson AR, Gatenby RA, Morse DL. The biology underlying molecular imaging in oncology: from genome to anatome and back again. Clin Radiol. 2010;65(7):517–21.PubMedPubMedCentralCrossRef
68.
Zurück zum Zitat Zwanenburg A, Valliéres M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295(2):328–38.PubMedCrossRef Zwanenburg A, Valliéres M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295(2):328–38.PubMedCrossRef
70.
Zurück zum Zitat Lacroix M, Frouin F, Dirand AS, Nioche C, Orlhac F, Bernaudin JF, et al. Correction for magnetic field inhomogeneities and normalization of voxel values are needed to better reveal the potential of MR radiomic features in lung cancer. Front Oncol. 2020;10:43.PubMedPubMedCentralCrossRef Lacroix M, Frouin F, Dirand AS, Nioche C, Orlhac F, Bernaudin JF, et al. Correction for magnetic field inhomogeneities and normalization of voxel values are needed to better reveal the potential of MR radiomic features in lung cancer. Front Oncol. 2020;10:43.PubMedPubMedCentralCrossRef
71.
Zurück zum Zitat Liu H, Dougherty ER, Dy JG, Torkkola K, Tuv E, Peng H, et al. Evolving feature selection. IEEE Intelligent Systems. 2005;20(6):64–76 (Conference Name: IEEE Intelligent Systems.).CrossRef Liu H, Dougherty ER, Dy JG, Torkkola K, Tuv E, Peng H, et al. Evolving feature selection. IEEE Intelligent Systems. 2005;20(6):64–76 (Conference Name: IEEE Intelligent Systems.).CrossRef
Metadaten
Titel
A common [18F]-FDG PET radiomic signature to predict survival in patients with HPV-induced cancers
verfasst von
Stephane Niyoteka
Romain-David Seban
Rahimeh Rouhi
Andrew Scarsbrook
Catherine Genestie
Marion Classe
Alexandre Carré
Roger Sun
Agustina La Greca Saint-Esteven
Cyrus Chargari
Jack McKenna
Garry McDermott
Eirik Malinen
Stephanie Tanadini-Lang
Matthias Guckenberger
Marianne G. Guren
Claire Lemanski
Eric Deutsch
Charlotte Robert
Publikationsdatum
26.08.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 13/2023
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-023-06320-2

Weitere Artikel der Ausgabe 13/2023

European Journal of Nuclear Medicine and Molecular Imaging 13/2023 Zur Ausgabe